Patient Death Reported in Bristol's Early MS CAR-T Trial
BMY sits 45% above its 52-week low of $42.52.
Summary
A patient has died in an early-stage trial of Bristol's CAR-T therapy for multiple sclerosis, per a Seeking Alpha report. This builds on the company's voluntary pause of the Zola-Cel autoimmune CAR-T program, which it halted in early June after life-threatening ICANS (brain inflammation) cases. A death is a harder safety fact than the pause itself and raises the bar for the program's path forward. Bristol is a large, diversified pharma, so the financial exposure is limited relative to its revenue base, but the read-through for its cell-therapy pipeline and any autoimmune CAR-T ambitions is negative.
At the time of this announcement, BMY was trading at $61.84 on NYSE in the Life Sciences sector, with a market capitalization of approximately $125.6B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.